Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Status:
Completed
Trial end date:
2020-03-24
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety and feasibility of weekly
intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian
cancer, Fallopian tube cancer or primary peritoneal cancer. The study also aims to determine
the maximum tolerated dose of Cantrixil in these patients when administered as a monotherapy
or a combination therapy.